Loading clinical trials...
Loading clinical trials...
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Conditions
Interventions
Evacetrapib
Atorvastatin
+2 more
Locations
64
United States
Heart Center Research, LLC
Huntsville, Alabama, United States
Desert Clinical Research
Mesa, Arizona, United States
Central Phoenix Med Clinic LLC
Phoenix, Arizona, United States
Advanced Clinical Research
Carmichael, California, United States
Tooraj Joseph Raoof M.D., Inc.
Encino, California, United States
Irvine Clinical Research Center
Irvine, California, United States
Start Date
October 1, 2014
Primary Completion Date
December 1, 2015
Completion Date
December 1, 2015
Last Updated
October 8, 2019
NCT06062394
NCT07230730
NCT07334834
NCT07311941
NCT06903897
NCT06055036
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions